Embattled Mylan Boosts EpiPen Patient Programs, Doesn't Budge on Price | NBC Connecticut
National & International News
The day’s top national and international news

Embattled Mylan Boosts EpiPen Patient Programs, Doesn't Budge on Price

Mylan has hiked prices for EpiPen as frequently as three times a year over the past nine years

    processing...

    NEWSLETTERS

    You’ve probably heard about the cost of the life-saving Epipen skyrocketing. Now the drug maker is promising discounts, but they’re not the only manufacturer in town. There’s also a cheaper alternative. Roseanne Colletti reports. (Published Thursday, Aug. 25, 2016)

    Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has soared over the past decade. 

    But the drugmaker didn't budge on its price hikes Thursday, which have drawn ire both in Congress and from families that have had to shell out increasingly large sums for the potentially life-saving treatment. 

    Drive-Thru Pot Dispensary Opens in Colorado

    [NATL] Drive-Thru Pot Dispensary Opens in Colorado

    When you think of a drive-thru, fast food probably comes to mind. But what about marijuana? Tumbleweed Express Drive-Thru in Parachute, Colorado, is the first of its kind. After nearly a year of preparation, the drive-thru pot shop opened for business on 4/20. 

    "Their timing couldn't have been better in my opinion, I mean everybody wants to celebrate," said Kyle Steele, a customer at the drive-thru.

    (Published Friday, April 21, 2017)

    That means the insurers and employers that pay the bulk of the EpiPen cost for many patients will continue to do so, contributing to higher health insurance costs. 

    "That's just going to come out in the premiums," said Sabrina Corlette, a research professor at the Georgetown University's Health Policy Institute. "Everybody suffers, except the Mylan investors." 

    Mylan joins a growing list of drugmakers, Turing Pharmaceuticals and Valeant Pharmaceuticals International Inc. among them, that have been called out after mammoth price hikes for the drugs they sell, with little or no innovation. 

    Turing's former CEO Martin Shkreli became the poster child of pharmaceutical-industry greed last fall for hiking the price of a life-saving drug, Daraprim, by more than 5,000 percent. 

    Protester, Official React to Arkansas Execution

    [NATL] Protester, Official React to Arkansas Execution

    Just before midnight Thursday, Arkansas announced it had executed death row inmate Ledell Lee. He is the first of four inmates scheduled to die before the end of the month when a crucial lethal injection drug is set to expire. A protester and a spokesperson for the governor reacted to the controversial execution.

    (Published Friday, April 21, 2017)

    He has applauded Mylan's actions. 

    The average price of a two-dose EpiPen package climbed to about $608 earlier this year, up more than 500 percent from around $94 nine years ago, according to the Elsevier Clinical Solutions' Gold Standard Drug Database. 

    Mylan CEO Heather Bresch told CNBC Thursday that lowering the price was not an option. 

    "Had we reduced the list price, I couldn't ensure that everyone who needs an EpiPen gets one," she said. 

    Missing 15-Year-Old Girl Found, Teacher Arrested

    [NATL] Missing 15-Year-Old Girl Found, Teacher Arrested

    A missing 15-year-old girl was found in California after a month-long search. She was found with the Tennessee teacher who is accused of kidnapping her.

    (Published Thursday, April 20, 2017)

    EpiPens are used in emergencies to treat severe allergies that can lead to anaphylactic shock. Roughly 40 million Americans have severe allergies to spider bites, bee stings and foods like nuts, eggs and shellfish. 

    Democratic presidential candidate Hillary Clinton and members of Congress from both parties have quickly ramped up criticism of the price Mylan charges for the medicine. 

    Clinton said Wednesday that pharmaceutical and biotech industries can fuel American innovation, and combat debilitating diseases. But she added that "it's wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them." 

    Bresch said Thursday that Mylan gets $274 for a two-dose EpiPen package. The rest of the $608 price goes to entities that stand between the drugmaker and the patient, like insurers, pharmacy benefits managers, wholesalers and drugstores. 

    Bill O'Reilly Ousted At Fox News Channel

    [NATL] Bill O'Reilly Ousted At Fox News Channel

    Fox News host Bill O'Reilly was officially pushed out at the network. This comes after O'Reilly had paid out more than $13 million to five different women over allegations of sexual harassment. In a statement, 21st Century Fox said, "After a thorough and careful review of the allegations, the Company and Bill O’Reilly have agreed that Bill O’Reilly will not be returning to the Fox News Channel." O'Reilly has denied any wrongdoing.

    (Published Wednesday, April 19, 2017)

    "This isn't an EpiPen issue," she said. "This isn't a Mylan issue. This is a health care issue." 

    However, it is Mylan that is increasing the price of the drug and the company stuck by those price hikes Thursday. 

    That stance brought a wave of new money from investors who drove Mylan's shares up more than 2 percent in morning trading, while major U.S. indexes slipped. 

    Last year, more than 3.6 million U.S. prescriptions for two-packs of EpiPens were filled, according to data firm IMS Health. That brought in sales of nearly $1.7 billion for Mylan. 

    Columbia Student Opens Restaurant in Dorm Room

    [NY-NATL] Columbia Student Opens Restaurant in Dorm Room

    Pith, a small bistro created by Columbia senior Jonah Reider and run out of his dorm room's communal kitchen, is the hottest restaurant in town after opening just two weeks ago. John Chandler reports.

    (Published Thursday, April 20, 2017)

    Mylan said Thursday that it was doubling the eligibility for its patient assistance program to people with incomes four times higher than the federal poverty level. It said that means a family of four making up to $97,200 would pay nothing out of pocket for the treatment. It also noted that its $300 savings card would cut the bill in half for patients who would otherwise have to pay full price for the EpiPen. 

    Patients also will be able to order the injected medicine directly from the company, to help lower costs. 

    These measures could provide significant help for people with no coverage facing the full bill. But they might have more limited value to a patient whose insurer will cover most of the bill anyway and whose future premium could be affected by the drug's price. 

    Customers of Express Scripts Holding Co., the nation's largest pharmacy benefits manager, pay about $73.50 out of pocket for an EpiPen prescription, spokesman Brian Henry said. He noted that price has stayed relatively stable the past couple years. 

    Sen. Richard Blumenthal, D-Connecticut, dismissed the actions Mylan detailed Thursday as a baby step. 

    "This step seems like a PR fix more than a real remedy, masking an exorbitant and callous price hike," the senator said in a statement.